Drug Profile
Research programme: therapeutic HCV vaccines - Profectus Biosciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Developer National Institute of Allergy and Infectious Diseases; Profectus Biosciences
- Class Hepatitis C vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hepatitis C
Most Recent Events
- 12 Sep 2023 Preclinical development in Hepatitis-C(Adjunctive treatment) is ongoing in USA (Parenteral) (Auro-vaccines pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hepatitis-C(Adjunctive treatment) in USA (Parenteral)
- 27 Jul 2016 Preclinical trials in Hepatitis C (Adjunctive treatment) in USA (Parenteral)